Join Akebia Therapeutics for a virtual R&D Day featuring scientific experts James A. Tumlin, MD (NephroNet), V. Michael Holers, MD (University of Colorado Anschutz) and Jonathan Barratt, MD, PhD, FRCP (University of Leicester), who will join management to discuss Akebia’s robust pipeline of clinical stage kidney diseases programs:

• Praliciguat, a soluble guanylate cyclase stimulator currently in a Phase 2 clinical trial, targeting Focal Segmental Glomerulosclerosis (FSGS).
• AKB-097, a next-generation tissue-targeted complement inhibitor planned to enter a Phase 2 basket trial in rare kidney disease, including IgA nephropathy, lupus nephritis and C3 glomerulopathy, in the second half of 2026.
• AKB-9090, a hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor entering a Phase 1 clinical trial in acute kidney injury (AKI) associated with cardiac surgery, in the first half of 2026.

Company management and scientific experts will review the unmet need and current treatment landscape for these rare kidney diseases and discuss the mechanisms of action, supporting data and differentiation of the product candidates.